ContributorsPublishersAdvertisers

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Nature.com
 2021-11-20

Cover picture for the articleProteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM). Methods. The safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100"‰mg)"‰+"‰carfilzomib (56 or 70"‰mg/m2)"‰+"‰dexamethasone...

www.nature.com

Comments / 0

Comments / 0